Capsid-like supramolecular dendritic systems as pH-responsive nanocarriers for drug penetration and site-specific delivery

详细信息    查看全文

• 作者：Yachao Li ; BS ; Yusi Lai ; PhD ; Xianghui Xu ; PhD ; ^{xianghui.xu@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Xiao Zhang ; MS ; Yahui Wu ; MS ; Cheng Hu ; BS ; Zhongwei Gu ; MS ; ^{zwgu@scu.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Bioinspired nanocarriers ; Supramolecular dendritic system ; pH-responsive controlled release ; Site-specific delivery ; Drug penetration
• 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：12
• 期：2
• 页码：355-364
• 全文大小：2044 K

文摘

Supramolecular dendritic systems emerge as a promising new-generation bioinspired nanoplatform for nanomedicine. Herein, we report capsid-like mimics self-assembled from peptide dendrimers and functionalized peptides to enhance drug penetration and site-specific delivery for tumor therapy. These drug-loaded supramolecular dendritic systems are endowed with capsid-like component and nanostructure by a facile supramolecular approach. As expected, the drug-loaded capsid-like nanocarriers show some desirable advantages for antitumor drug delivery: a) well-defined nanostructure to improve drug location at tumor site, b) capsid-like architecture to enhance drug penetration, c) high internalization, pH-controlled release and nuclear delivery to jointly achieve site-specific delivery. Based on these merits, the drug-loaded capsid nanocarriers provide efficient tumor suppression to 4T1 tumor bearing BALB/c mice and decrease the DOX-induced toxicity during treatment course.

From the Clinical Editor

Dendrimers have been tested in many clinical trials as nanocarriers, without great success due to many limitations. Here, the authors attempted to address these issues by developing supramolecular dendritic systems, which mimic capsids in viruses. Both in-vitro and in-vivo studies showed promising results. This work should provide a platform for further development of dendrimer-based nanocarriers for drug delivery.